Abstract:Objective To compare the immune effects of Coxsackievirus B3 (CVB3) capsid protein VP1 expressed bacterially, recombinant adenovirus rAd/VP1 and recombinant plasmid pcDNA3/VP1which express VP1 protein in mice. Methods After expressed in prokaryotic cells, VP1 protein was purified. Recombinant adenovirus rAd/VP1 and recombinant plasmid pcDNA3/VP1 were amplified and extracted. Six to 8-week-old, male BALB/c mice were divided into four groups randomly. Each group contained 18 mice. The mice of pcDNA3/VP1 group or VP1 protein group were immunized intramuscularly with three injections at three weeks apart, of recombinant plasmid pcDNA3/VP1 at a dose of 100 μg/mouse or recombinant protein VP1 at a dose of 50 μg/mouse. The mice of rAd/VP1 group were immunized intramuscularly twice at two weeks interval with rAd/VP1 at a dose of 1.2 × 107 PFU. The control group was mock-immunized with 100 μl of PBS intramuscularly. Mice were bled from the retroorbital sinus plexus every two weeks after each immunization. ELISA and micro-neutralization test were used to detect levels of CVB3-specific IgG antibody and neutralizing antibody titers in the sera of immunized mice. Three weeks after the last immunization, the cytotoxic T lymphocyte(CTL) killing activity of spleen lymphocytes was detected with CCK-8 assay. Subsequently, virus titers in the sera of immunized mice were determined by the 50% cell culture infective dose( CCID50 ) assay on HeLa cell monolayers and percentage of animals surviving were observed after lethal CVB3 attack over a period of 21 days. Results The titers of specific IgG antibody and neutralizing antibody in sera of VP1 protein immunized mice were higher than other groups( P ＜0.05 ). While CTL killing activity of spleen lymphocytes of VP1 protein immunized mice was lower than mice in rAd/VP1 group( P ＜0. 05). Virus titers in sera of VP1 protein immunized mice were lower than the mice in pcDNA3/VP1 or rAd/VP1 groups ( P ＜ 0.05 ), while survival rate was significantly higher than these two groups ( P ＜ 0.05 ).Conclusion VP1 protein induced higher level of humoral immune response and acquired obvious immune protection effects in mice. The immunizing potency of VP1 protein vaccine surpassed plasmid pcDNA3/VP1or recombinant adenovirus rAd/VP1. It appeared to be a promising candidate among the three different vaccines.

[Immune Effects of Four Coxsackievirus B3 VP1 DNA Fusion Vaccines in Mice].

Study on Immunological Effect Fusion DNA Vaccine Pcdna3/mdc-Vp1 on CVB3 in Mice

Comparison on Immune Effects of MDC-VP1 and STxB-VP1 DNA Vaccine in Mice

Study on Immunological Effect of DNA Vaccine Expressing Fusion Protein MDC-CVB3VP1 with Different Linker Length

The Immunological Effect of Ad/MDC-VP1 Combined with DNA Vaccine Against Coxsackievirus Infection

[Study on Combined Immunization of Rad/mdc-Vp1 and Pcdna3/mdc-Vp1 Against Coxsackievirus B3 Challenge in Mice].

Comparison of the Immune Effects of Coxsackievirus B3 VP1 Protein, Rad/vp1 and Pcdna3/vp1 in Mice

Comparative immunogenicity of subunit vaccine expressing CVB3 VP1 and targeted gene vaccine in mice

[Protective immunoresponse to CVB3 induced by gene immunization with pcDNA3-VP1].

Effect of mouse IFN-γ gene adjuvant on immunogenic enhancement of secreting coxsackievirus B3 VP1 DNA vaccine

[The Effects of Inoculation Route and Adjuvant Type on the Immunizing Potency of CVB3 VP1 Protein].

Expression of CVB3 VP1 Protein in Prokaryotic System and Study on Its Immune Effects

Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.

Construction of Targeting DNA Vaccine Pcdna3/mdc-Vp1 and Its Immunological Effect on Mice

IMMUNE ENHANCING EFFECT OF INTERLEUKIN-2 GENE ADJUVANT ON COXSACKIEVIRUS B3 VP1 DNA VACCINE

Influence of FMDV epitopes-hsp70 fusion protein on immune responses in mice

Construction of the Recombinant Adenovirus Expressing the CVB3 Svp1-C3d3 Protein and Study on Its Immunological Effects in Mice

Effect of interleukin-2 and interleukin-15 gene as adjuvant on coxasckievirus B3 VP1 DNA vaccine

[Fusion Expression of O Type Foot-and-mouth Diseases Virus VP1 Gene and HSP70 Gene and Induction of Immune Responses in Mice].

[A Novel DNA Vaccine Containing Endosome-Fusogenic Peptide Prevents CVB3-induced Myocarditis in Mice].

Enhancement of Mouse Immune Response by Recombinant Adenovirus Co-Expressing VP1-2A of Foot-and-mouth Disease Virus and Porcine IFN-α